Rik Ossenkoppele
111 – 120 of 168
- show: 10
- |
- sort: year (new to old)
Close
Embed this list
<iframe src=" "
width=" "
height=" "
allowtransparency="true"
frameborder="0">
</iframe>
- 2021
-
Mark
Mesial temporal tau is related to worse cognitive performance and greater neocortical tau load in amyloid-β–negative cognitively normal individuals
(
- Contribution to journal › Article
-
Mark
The impact of demographic, clinical, genetic, and imaging variables on tau PET status
(
- Contribution to journal › Article
-
Mark
2020 update on the clinical validity of cerebrospinal fluid amyloid, tau, and phospho-tau as biomarkers for Alzheimer’s disease in the context of a structured 5-phase development framework
(
- Contribution to journal › Scientific review
-
Mark
The validation status of blood biomarkers of amyloid and phospho-tau assessed with the 5-phase development framework for AD biomarkers
(
- Contribution to journal › Scientific review
-
Mark
The strategic biomarker roadmap for the validation of Alzheimer’s diagnostic biomarkers : methodological update
(
- Contribution to journal › Article
-
Mark
Neuropsychiatric and Cognitive Symptoms Across the Alzheimer Disease Clinical Spectrum: Cross-sectional and Longitudinal Associations
(
- Contribution to journal › Debate/Note/Editorial
- 2020
-
Mark
Distinct tau PET patterns in atrophy-defined subtypes of Alzheimer's disease
(
- Contribution to journal › Article
-
Mark
Test–retest repeatability of [18F]Flortaucipir PET in Alzheimer’s disease and cognitively normal individuals
(
- Contribution to journal › Article
-
Mark
Diagnostic Performance of RO948 F 18 Tau Positron Emission Tomography in the Differentiation of Alzheimer Disease from Other Neurodegenerative Disorders
(
- Contribution to journal › Article
-
Mark
Tau pathology and relative cerebral blood flow are independently associated with cognition in Alzheimer’s disease
(
- Contribution to journal › Article